Skip to main content

Advertisement

SpringerLink
Log in

Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

CXC ligand 13 (CXCL13) is known as B cell chemotactic factor (BLC), promoting the migration of B lymphocytes by communicating with its receptor CXCR5, which can be regarded as part of pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This meta-analysis was to evaluate the circulating CXCL13 levels in SLE and RA.

Methods

All articles were respectively gathered from PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) (by the end of 10 April 2019). According to random effects model, standardized mean difference (SMD) and 95% confidence interval (CI) of CXCL13 levels in SLE and RA were calculated by Stata 12.0 software.

Results

Totally, 15 studies were selected (981 SLE patients and 380 healthy controls, 332 RA patients and 147 healthy controls). SLE and RA patients were significantly increased in circulating CXCL13 levels (SMD = 1.851, 95% CI 0.604–3.098; SMD = 1.801, 95% CI = 1.145–2.457). Subgroup analyses showed that SLE patients from the Chinese group and systemic lupus erythematosus disease activity index (SLEDAI) score ≥ 6 group had higher circulating CXCL13 levels (SMD = 2.182, 95% CI 0.135–4.229; SMD = 0.767, 95% CI 0.503–1.030). However, there were no significant changes in CXCL13 concentrations in SLE patients from the English and SLEDAI score < 6 group. Similarly, subgroup analyses presented that RA patients from different classifications showed higher circulating CXCL13 levels. There was no publication bias.

Conclusions

This meta-analysis demonstrated increased circulating CXCL13 concentrations in SLE and RA patients. Circulating CXCL13 levels may act as biomarkers and therapy targets in the diagnosis and treatment of SLE and RA.

Key Point

• First, CXC ligand 13 (CXCL13) is closely related to the pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), Second, this study may provide novel therapeutic targets for the treatment of SLE and RA patients. This meta-analysis provides a comprehensive analysis of circulating CXCL13 levels in patients with SLE and RA and also explores related influencing factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Coronel-Restrepo N, Posso-Osorio I, Naranjo-Escobar J, Tobón GJ (2017) Autoimmune diseases and their relation with immunological, neurological and endocrinological axes. Autoimmun Rev 16(7):684–692. https://doi.org/10.1016/j.autrev.2017.05.002

    Article  CAS  PubMed  Google Scholar 

  2. Agmon-Levin N, Blank M, Paz Z, Shoenfeld Y (2009) Molecular mimicry in systemic lupus erythematosus. Lupus 18(13):1181–1185. https://doi.org/10.1177/0961203309346653

    Article  CAS  PubMed  Google Scholar 

  3. D’Cruz DP, Khamashta MA, Hughes GR (2007) Systemic lupus erythematosus. Lancet 369(9561):587–596

    Article  PubMed  Google Scholar 

  4. Chinses Society of rheumatology (2003) Guidelines for the diagnosis and treatment of systemic lupus erythematosus. Chin J Rheumatol 7(8):508–513

    Google Scholar 

  5. Fortuna G, Brennan MT (2013) Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin N Am 57(4):631–655. https://doi.org/10.1016/j.cden.2013.06.003

    Article  PubMed  Google Scholar 

  6. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/s0140-6736(16)30173-8

    Article  CAS  PubMed  Google Scholar 

  7. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H, Ochi T (2001) Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 166(1):650–655. https://doi.org/10.4049/jimmunol.166.1.650

    Article  CAS  PubMed  Google Scholar 

  8. Zhang X, Yang CX (2016) Research progress of CXCL-13 antibody in the treatment of autoimmune disease. Pract Pharm Clin Remed 19(8):1046–1049. https://doi.org/10.14053/j.cnki.ppcr.201608032

    Article  Google Scholar 

  9. Schiffer L, Worthmann K, Haller H, Schiffer M (2015) CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis from bench to bedside? Clin Exp Immunol 179(1):85–89. https://doi.org/10.1111/cei.12439

    Article  CAS  PubMed  Google Scholar 

  10. Li LL (2016) Studies on the relationship between CXCL13 and systemic lupus erythematosus. J Nantong Univ (Med Sci) 36(4):287–290. https://doi.org/10.16424/j.cnki.cn32-1087/r.2016.04.013

    Article  CAS  Google Scholar 

  11. Worthmann K, Gueler F, von Vietinghoff S, Davalos-Mißlitz A, Wiehler F, Davidson A, Witte T, Haller H, Schiffer M, Falk CS, Schiffer L (2014) Pathogenetic role of glomerular CXCL13 expression in lupus nephritis. Clin Exp Immunol 178(1):20–27. https://doi.org/10.1111/cei.12380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Luo DH, Wan X, Liu JM, Tong TJ (2017) How to estimate he sample mean and standard deviation from the sample size, median, extremes or quartiles. Chin J Evid Based Med 17(11):1350–1355

    Google Scholar 

  13. Schiffer L, Kümpers P, Davalos-Misslitz AM, Haubitz M, Haller H, Anders HJ, Witte T, Schiffer M (2009) B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus(SLE). Nephrol Dial Transplant 24(12):3708–3712. https://doi.org/10.1093/ndt/gfp343

    Article  CAS  PubMed  Google Scholar 

  14. Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, Tsai CY (2010) Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 37(1):45–52. https://doi.org/10.3899/jrheum.090450

    Article  CAS  PubMed  Google Scholar 

  15. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW (2010) Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 30(1):45–52. https://doi.org/10.1007/s10875-009-9325-5

    Article  CAS  PubMed  Google Scholar 

  16. Schiffer L, Kielstein JT, Haubitz M, Lührs H, Witte T, Haller H, Kümpers P, Schiffer M (2011) Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus 20(5):507–511. https://doi.org/10.1177/0961203310383301

    Article  CAS  PubMed  Google Scholar 

  17. Run YM, Rao H, Jiang H, Zhu YF, Cao H, Wang JM (2015) Detection of serum chemokine CXCL family contents in patients with systemic lupus erythematosus and its clinical significance. J Hainan Med Univ 21(12):1733–1736. https://doi.org/10.13210/j.cnki.jhmu.20150827.006

    Article  Google Scholar 

  18. Xie WY, Nie LP, Yang YH (2015) The study of circulating CXCL13 level and expression of its receptor CXCR5 with system lupus erythematosus. Chin J Lab Diagn 19(10):1689–1692.6

    Google Scholar 

  19. Dong DQ, Zhang JM, Li HY, Sun WK (2016) Expressions of CXCR5 mRNA and CXCL13 mRNA in patients with systemic lupus erythematosus. Chin J Clinic (Electronic Edition) 10(18):2700–2704. https://doi.org/10.3877/cma.j.issn.1674-0785.2016.18.005

    Article  Google Scholar 

  20. Fang C, Luo T, Lin L (2017) The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: a STROBE-compliant article. Medicine(Baltimore) 96(48):e8675. https://doi.org/10.1097/MD.0000000000008675

    Article  CAS  Google Scholar 

  21. He DN, Hu JK, Zhu JR, Dai SH, Liu YW, Hu N (2018) Serum CXCL13 and renal involvement in lupusc nephritis. Jiangxi Med J 53(8):822–824+833. https://doi.org/10.3969/j.issn.1006-2238.2018.8.012

    Article  Google Scholar 

  22. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 58(8):2257–2267. https://doi.org/10.1002/art.23667

    Article  CAS  PubMed  Google Scholar 

  23. Ahmed SF, Badr T, Hosny SM, Hamayed HFA (2013) Assessment of synovitis in early rheumatoid arthritis by CXCL13 serum levels and power Doppler ultrasonography: correlation with disease activity. Egypt Rheumatologist 35(1):21–27. https://doi.org/10.1016/j.ejr.2012.09.001

    Article  Google Scholar 

  24. Sherif NM, Arafa MM, Ibrahim SE, Moussa SG (2013) CXC ligand 13 in rheumatoid arthritis and its relation to secondary Sjögren’s syndrome. Egypt Rheumatologist 35(3):121–126. https://doi.org/10.1016/j.ejr.2013.03.004

    Article  Google Scholar 

  25. Zhang MM, Zhang R, Xu JH (2013) Study of serum IL32 and chemokine CXCL13 in patients with rheumatoid arthritis. Acta Univ Med Anhui 48(12):1512–1515. https://doi.org/10.19405/j.cnki.issn1000-1492.2013.12.024

    Article  CAS  Google Scholar 

  26. An LM, Chu TS, Liu W, Liu B, Zhu Q (2018) Expression and significance of serum CXCL13 in rheumatoid arthritis. J Chin Pract Diagn 32(3):248–250. https://doi.org/10.13507/j.issn.1674-3474.2018.03.012

    Article  Google Scholar 

  27. Allam SI, Sallam RA, Elghannam DM, El-Ghaweet AI (2019) Clinical significance of serum B cell chemokine (CXCL13) in early rheumatoid arthritis patients. Egypt Rheumatologist 41(1):11–14. https://doi.org/10.1016/j.ejr.2018.04.003

    Article  Google Scholar 

  28. Worthmann K, Gueler F, von Vietinghoff S, Davalos-MiBlitz A, Wiehler F, Davidson A, Witte T, Haller H, Schiffer M, Falk CS, Schiffer L (2014) Pathogenetic role of glomerular CXCL13 expression in lupus nephritis. Clin Exp Immunol 178(1):20–27. https://doi.org/10.1111/cei.12380

    Article  CAS  Google Scholar 

  29. Oglesby A, Shaul AJ, Pokora T, Paramore C, Cragin L, Dennis G, Narayanan S, Weinstein A (2013) Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol:347520. https://doi.org/10.1155/2013/347520

    Article  Google Scholar 

  30. Latek D, Modzelewska A, Trzaskowski B, Palczewski K, Filipek S (2012) G protein-coupled receptors--recent advances. Acta Biochim Pol 59(4):515–529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ishikawa S, Sato T, Abe M, Nagai S, Onai N, Yoneyama H, Zhang Y, Suzuki T, Hashimoto S, Shirai T, Lipp M, Matsushima K (2001) Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 193(12):1393–1402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wu X, Guo J, Ding R, Lv B, Bi L (2015) CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice. Acta Histochem 117(8):732–737. https://doi.org/10.1016/j.acthis.2015.09.001

    Article  CAS  PubMed  Google Scholar 

  33. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581

    Article  CAS  PubMed  Google Scholar 

  34. Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, Ménard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF (2014) Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther 16(2):R103. https://doi.org/10.1186/ar4552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, Sakellariou G, Montecucco C, Caporali R (2012) Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther 14(1):R34. https://doi.org/10.1186/ar3742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bugatti S, Manzo A, Vitolo B, Benaglio F, Binda E, Scarabelli M, Humby F, Caporali R, Pitzalis C, Montecucco C (2014) High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology (Oxford) 53(10):1886–1895. https://doi.org/10.1093/rheumatology/keu163

    Article  CAS  Google Scholar 

  37. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL (2011) CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology(Oxford) 50(3):603–610. https://doi.org/10.1093/rheumatology/keq337

    Article  CAS  Google Scholar 

  38. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6(8):468–476. https://doi.org/10.1038/nrrheum.2010.86

    Article  CAS  PubMed  Google Scholar 

  39. Wang JB, Pan HF, Ye DQ (2018) Association of lnc5150 gene polymorphisms with systemic lupus erythematosus. Chin J Dis Control Prev 22(9):929–932. https://doi.org/10.16462/j.cnki.zhjbkz.2018.09.014

    Article  Google Scholar 

  40. Huang LL, Xu JH, Xu SQ, Xiao H, Chang L, Liu N, Ma Q (2016) Treat-to-target of rheumatoid arthritis and potential determinants. Chin J Dis Control Prev 20(6):586–589. https://doi.org/10.16462/j.cnki.zhjbkz.2016.06.012

    Article  Google Scholar 

  41. Han JH, Suh CH, Jung JY, Nam JY, Kwon JE, Yim H, Kim HA (2015) Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset still’s disease. Arthritis Res Ther 17:260. https://doi.org/10.1186/s13075-015-0773-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Thanks to the selfless help of the lab teachers and classmates.

Funding

This meta-analysis was funded by the Chinese national high level personnel special support plan.

Author information

Author notes

  1. Yu-Qing Bao and Jun-Ping Wang contributed equally to this work.

Authors and Affiliations

  1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China

    Yu-Qing Bao, Jun-Ping Wang, Zi-Wei Dai, Yan-Mei Mao, Jun Wu, Heng-Sheng Guo, Yuan-Rui Xia & Dong-Qing Ye

  2. Anhui Province Key Laboratory of Major Autoimmune Diseases, 81 Meishan Road, Hefei, 230032, Anhui, China

    Yu-Qing Bao, Jun-Ping Wang, Yan-Mei Mao, Jun Wu, Heng-Sheng Guo, Yuan-Rui Xia & Dong-Qing Ye

Authors
  1. Yu-Qing Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-Ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zi-Wei Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan-Mei Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heng-Sheng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuan-Rui Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dong-Qing Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-Qing Ye.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bao, YQ., Wang, JP., Dai, ZW. et al. Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Clin Rheumatol 39, 281–290 (2020). https://doi.org/10.1007/s10067-019-04775-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-019-04775-z

Keywords

Search

Navigation